Skip to main content
. 2019 Jul 11;101(5):1018–1030. doi: 10.1093/biolre/ioz119

Figure 4.

Figure 4

p38 Mitogen-activated protein kinase-dependent inactivation of P-GSK3β in AECs and AMCs. (A) WBs of CSE and CSE + SB203580 (SB)-treated AECs for P-GSK3β, total GSK3β, β-Cat, and Nrf2. (B) WBs of CSE and CSE + SB-treated AMCs for P-GSK3β, total GSK3β, β-Cat, and Nrf2. The relative levels of β-Cat were unchanged (AECs and AMCs) while that of Nrf2 was attenuated (AMCs) in response to treatment with SB. Total GSK3β was used for normalization. (C) WBs for β-Cat and Nrf2 in response to GSK3β inhibitor CHIR99021 (CHIR) in AECs. (D) WBs for β-Cat and Nrf2 in response to GSK3β inhibitor CHIR in AMCs. Total cellular β-actin was used for normalization. The relative levels of β-Cat or Nrf2 remained unchanged in AMCs. In AECs, however, the expression of both β-Cat (P = 0.08) and Nrf2 (P = 0.08) showed an increasing trend in response to treatment with CHIR. Representative blots from a minimum n = 4 for each cell type are shown. Data are presented as mean ± SEM.